Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

October 3rd 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

October 1st 2020

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Breast Cancer Research Foundation Awards Fourth Research Grant at Yale

October 1st 2020

The Breast Cancer Research Foundation has awarded a 1-year, $175,000 research grant to Yale Cancer Center to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer

September 28th 2020

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Q&A: Practical Considerations in HER2+ Breast Cancer

September 24th 2020

The Impact of Subcutaneous Option for HER2+ BC

September 24th 2020

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

September 24th 2020

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

September 24th 2020

Administration of Dual HER2-Targeted Therapy in BC

September 24th 2020

Dual HER2-Targeted Approaches in Breast Cancer

September 24th 2020

Historic Perspectives on HER2+ Breast Cancer

September 24th 2020

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses the final overall survival results from the randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Management of Adverse Effects in R/R HER2+ mBC

September 23rd 2020

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

September 23rd 2020

HER2-targeted Therapy: Routes of Administration

September 23rd 2020

Practical Management of Early Stage HER2+ Breast Cancer

September 23rd 2020

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

September 21st 2020

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

September 21st 2020

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Significant Improvement in PFS Seen With Palbociclib/Fulvestrant in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21st 2020

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.